



## ESC Declaration of Interest Report

### 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the *ESC Declaration and Management of Conflict of Interest Policy*. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved by the ESC in July 2020.

The most up-to-date version of the policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI).

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Barbato Emanuele	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Coronary physiology</li> <li>- Abbott Vascular : Coronary physiology</li> <li>- Boston Scientific : Treatment of calcified coronary lesions</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Complex PCI procedures</li> <li>- Abbott : Coronary physiology</li> <li>- Insight Lifetech : Coronary physiology</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cassese Salvatore	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotic therapies</li> <li>- SIS Medical : Interventional cardiology</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- SIS Medical : Interventional cardiology</li> </ul>
De Hert Stefan	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Nordic : chair of the Data and Safety Monitoring Committee fo the NAPaR registry (aprotinin use in cardiac surgery)</li> </ul>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
De Laval Ingrid	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Geisler Tobias	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Anticoagulation, atrial fibrillation, vascular disease</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Geisler Tobias	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet therapy, Acute Coronary Syndrome, Heart Failure, Diabetes</li> <li>- Ferrer Internacional : Speaker Fees, Honoraria</li> <li>- Bristol Myers Squibb : Speaker Fees, Honoraria</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Speaker Fees, Honoraria</li> <li>- Academic CME : Speaker Fees, Honoraria</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic Foundation : Travel Fees Implanters Meeting</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Anticoagulation, vascular protection</li> <li>- Bristol Myers Squibb : Anticoagulation, ESUS</li> <li>- Medtronic : Atrial fibrillation, ESUS</li> <li>- Thieme Verlag : Editorial Board</li> <li>- Doctrinamed : Thrombosis</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation, atrial fibrillation, vascular disease</li> <li>- Bayer AG : Anticoagulation, atrial fibrillation, vascular disease</li> <li>- Ferrer Internacional : Antiplatelet therapy, acute coronary syndrome</li> <li>- Medtronic : Valvular disease, TAVR</li> <li>- Edwards Lifesciences : Valvular Heart Disease, Mitral and Tricuspid intervention</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Geisler Tobias	<p><b>2021</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Speaker Fees, Honoraria</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic Foundation : Travel Fees Implanters Meeting</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Anticoagulation, vascular protection</li> <li>- Bristol Myers Squibb : Anticoagulation, ESUS</li> <li>- Astra Zeneca : Antiplatelet therapy</li> <li>- Medtronic : Atrial fibrillation, ESUS</li> <li>- Thieme Verlag : Editorial Board</li> </ul>
Hall Trygve Sundby	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : PCSK9-inhibitors</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Managing editor of the journal "Cardiology" (Karger).</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Hall Trygve Sundby	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Sanofi Aventis : PCSK9-inhibitors</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Managing editor of the journal "Cardiology" (Karger).</li> </ul>
Halvorsen Sigrun	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Sanofi Aventis : Lipidlowering</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart failure</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation -speaker fee</li> <li>- Bristol Myers Squibb : Anticoagulation- speaker fee</li> <li>- Novartis : heart failure - speaker fee</li> </ul>
Hinterbuchner Lynne	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Ibanez Borja	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Lenarczyk Radoslaw	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : speaker fee</li> </ul>
Mansmann Ulrich	<p><b>2020</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mansmann Ulrich	<p><b>2021</b></p> <p>Nothing to be declared</p>
McGreavy Paul	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Global Heart Hub ESC Patient Forum</li> </ul> <hr/> <p><b>2021</b></p> <p>Other Positions of Influence</p> <ul style="list-style-type: none"> <li>- UK NHS Clinical Commissioning Group Experts Advisory Forum / CVD Delivery Group - Lay Member.</li> </ul>
Mehilli Julinda	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : BVS</li> <li>- Biotronik : BVS</li> <li>- Astra Zeneca : PCI</li> <li>- Siemens Healthcare : PCI</li> <li>- Bristol Myers Squibb : PCI</li> <li>- Lilly/Daiichi Sankyo : PCI</li> <li>- Terumo Inc : PCI stents</li> <li>- Boston Scientific : structural - TAVI</li> <li>- Edwards Lifesciences : structural TAVI</li> <li>- Medtronic : structural TAVI</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : structural TAVI</li> </ul>



## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mehilli Julinda	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : antithrombotic drugs</li> <li>- Bayer Vital GmbH : antithrombotic drugs</li> <li>- Daiichi Sankyo Europe GmbH : antithrombotic drugs</li> <li>- SIS Medical AG : DEB</li> <li>- Biotronik : DES</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : TAVI</li> </ul>
Mueller Christian Eugen	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Daiichi Sankyo : Anticoagulants And Lipid lowering</li> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Astra Zeneca : Anti-Diabetics</li> <li>- Idorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Acon : Diagnostics</li> <li>- Osler : Diagnostics</li> <li>- Novartis : Heart Failure</li> <li>- Sanofi Aventis : Lipid lowering</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Amgen : Lipid-lowering</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Diagnostics</li> <li>- BRAHMS GmbH : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> <li>- Upstream Medical Technologies : Diagnostics, Myocardial ischemia, BASEL VIII</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Daiichi Sankyo : Anticoagulants And Lipid lowering</li> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Astra Zeneca : Anti-Diabetics</li> <li>- Idorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Acon : Diagnostics</li> <li>- Osler : Diagnostics</li> <li>- Novartis : Heart Failure</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Diagnostics</li> <li>- BRAHMS GmbH : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> <li>- quidel : Diagnostics</li> <li>- LSI Medience Corporation : Diagnostics</li> <li>- Upstream Medical Technologies : Diagnostics, Myocardial ischemia, BASEL VIII</li> </ul>
Muneretto Claudio	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Atricure : Atrial fibrillation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Llvanova : Heart valve</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Atricure : Atrial fibrillation</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Muneretto Claudio	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Livanova : Heart valve</li> </ul>
Niessner Alexander	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulation</li> <li>- Daiichi Sankyo : anticoagulation</li> <li>- Pfizer : anticoagulation</li> <li>- Bristol Myers Squibb : anticoagulation</li> <li>- Boehringer-Ingelheim : anticoagulation, antidiabetic therapy</li> <li>- Novo-Nordisk : antidiabetic therapy</li> <li>- Astra Zeneca : anti-thrombotic therapy, diabetes, heart failure</li> <li>- Lilly : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Diabetes</li> <li>- Gilead : rheumatology</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulation</li> <li>- Pfizer : anticoagulation</li> <li>- Astra Zeneca : Diabetes</li> <li>- Boehringer-Ingelheim : diabetes</li> <li>- Novo-Nordisk : Diabetes</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Niessner Alexander	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulation</li> <li>- Daiichi Sankyo : anticoagulation</li> <li>- Pfizer : anticoagulation</li> <li>- Bristol Myers Squibb : anticoagulation</li> <li>- Boehringer-Ingelheim : anticoagulation, antidiabetic therapy</li> <li>- Novo-Nordisk : antidiabetic therapy</li> <li>- Astra Zeneca : antitthrombotic therapy, diabetes, heart failure</li> <li>- Lilly : Diabetes</li> <li>- Merck Sharp &amp; Dohme : Diabetes</li> <li>- Gilead : rheumatology</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulation</li> <li>- Pfizer : anticoagulation</li> <li>- Astra Zeneca : Diabetes</li> <li>- Boehringer-Ingelheim : diabetes</li> <li>- Novo-Nordisk : Diabetes</li> </ul>
Potpara Tatjana	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Oral anticoagulation</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Potpara Tatjana	<b>2020</b> - Pfizer : Oral anticoagulation
	<b>2021</b> Nothing to be declared
Ristic Arsen	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Actavis : Heart failure - Astra Zeneca : Heart Failure (Forxiga) - Boehringer-Ingelheim : Heart Failure (Jardiance) - Merck Sharp & Dohme : Pulmonary hypertension - Hemofarm Stada : Pulmonary hypertension - Pfizer : Pulmonary hypertension, TTR Amyloidosis  Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Hemofarm Stada : Pulmonary hypertension - Pfizer : Pulmonary hypertension, TTR Amyloidosis  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - CSL Behring : Cardiovascular risk - Secondary prevention - Pfizer : Pulmonary hypertension - United Therapeutics : Pulmonary hypertension  Research funding (personal) from healthcare industry.For yourself - Resverlogix : Cardiovascular Events in High-Risk T2DM Subjects With CAD - CSL Behring : Cardiovascular Risk - Novo-Nordisk : Obesity

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Ristic Arsen	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Pfizer : Pulmonary hypertension</li> <li>- Arena/United Therapeutics : Pulmonary Hypertension</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Novartis : Heart failure</li> <li>- Berlin Chemie AG : Heart failure</li> <li>- Actavis : Heart failure</li> <li>- Astra Zeneca : Heart Failure (Forxiga)</li> <li>- Boehringer-Ingelheim : Heart Failure (Jardiance)</li> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> <li>- Sandoz : Pulmonary hypertension</li> <li>- Hemofarm Stada : Pulmonary hypertension</li> <li>- Pfizer : Pulmonary hypertension, TTR Amyloidosis</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- CSL Behring : Cardiovascular risk - Secondary prevention</li> <li>- Janssen-Cilag : Pulmonary hypertension</li> <li>- Pfizer : Pulmonary hypertension</li> <li>- United Therapeutics : Pulmonary hypertension</li> <li>- GossamerBio : Pulmonary hypertension</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Ristic Arsen	<p><b>2021</b></p> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Obesity</li> <li>- Pfizer : Pulmonary hypertension</li> <li>- Arena/United Thereapeutics : Pulmonary Hypertension</li> </ul>
Sade L Elif	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer, Jansenn : speaker honorarium fee to the University of Baskent</li> </ul> <hr/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Pfizer : speaker honorarium fee to the University of Baskent</li> </ul>
Schirmer Henrik	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Brilique</li> <li>- Novartis : Entresto</li> </ul> <hr/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> <li>- Amgen : Lipids</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> </ul>



## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Schuepke Stefanie	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Antiplatelet therapy</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Antithrombotic therapy</li> </ul>
Sillesen Henrik	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Anti-thromboti therapy</li> <li>- Bracco Pharmaceutical : Contrast ultrasound</li> <li>- Philips Ultrasound : Vascular ultrasound</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Anti-thrombotic</li> <li>- Cook Medical : Aortic stentgrafting</li> <li>- Philips Ultrasound : Vascular Ultrasound</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Healthcare - OTHER - My pension includes stock in Novo Nordisk, Genmab, Bavarian Nordic</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sillesen Henrik	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself - I give advice to Airfinity Ltd, a Life Science Analytics company.</p>
Skulstad Helge	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - OSLO UNIVERSITETSSYKEHUS HF : Cardiology</p> <hr/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Torracca Lucia	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Abbott : Valve diseases</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. For yourself - Edwards Lifesciences : cardiac surgery</p> <hr/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Abbott : Valve Disease - Edwards LiLifescience : Valve Disease</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Tutarel Oktay	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag : Pulmonary arterial hypertension in CHD</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Actelion : Quality of life in children with congenital heart disease and pulmonary arterial hypertension</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Janssen-Cilag : Pulmonary arterial hypertension in CHD</p>
Van Der Meer Peter	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Vifor International : comorbidities in Heart Failure - Pharma Nord : selenium supplements in HF</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pharmacosmos : iron deficiency - Vifor International : iron deficiency and hyperkalemia - Novartis : Sacubitril/valsartan - Boehringer-Ingelheim : sglT2 inhibitors</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Van Der Meer Peter	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : amyloidosis</li> <li>- Astra Zeneca : drugs for heart failure</li> <li>- Vifor International : iron deficiency and hyperkalemia</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Vifor International : comorbidities in Heart Failure</li> <li>- Pharma Nord : selenium supplements in HF</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : amyloidosis</li> <li>- Novo-Nordisk : diabetes and heart failure</li> <li>- Pharmacosmos : iron deficiency</li> <li>- Vifor International : iron deficiency and hyperkalemia</li> <li>- Novartis : Sacubitril/valsartan</li> <li>- Boehringer-Ingelheim : sglT2 inhibitors</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : amyloidosis</li> <li>- Astra Zeneca : drugs for heart failure</li> <li>- Pharma Nord : food supplements</li> <li>- Vifor International : iron deficiency and hyperkalemia</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Wojakowski Wojciech	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- MyoKardia Inc : HOCCM</li> <li>- Boehringer-Ingelheim : NOAC</li> <li>- Pfizer : NOAC</li> <li>- Abbott Vascular : OCT, RFR</li> <li>- Astra Zeneca : P2Y12 inhibitors, flozins</li> <li>- Biotronik : stents</li> <li>- Balton : stents/valvuloplasty balloons</li> <li>- Medtronic : TAVI, stents</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- MyoKardia Inc : HOCCM</li> <li>- Boehringer-Ingelheim : NOAC</li> <li>- Pfizer : NOAC</li> <li>- Abbott Vascular : OCT, RFR. MitraClip, TriClip</li> <li>- Astra Zeneca : P2Y12 inhibitors, flozins</li> <li>- Biotronik : stents</li> <li>- Balton : stents/valvuloplasty balloons/TAVI and PFO</li> <li>- Edwards Lifesciences : TAVI</li> <li>- Medtronic : TAVI, stents</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Zacharowski Kai	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Fresenius Kabi Deutschland GmbH : Anaesthesia</li> <li>- Vifor Pharma Deutschland GmbH : Anemia</li> <li>- Haemonetics : Consultant Patient Blood Management</li> <li>- Nordic Group : Independent contractor</li> <li>- CSL Behring : Patient Blood Management</li> <li>- Pharmacosmos : Patient Blood Management</li> <li>- Stiftung PBM Academy : Patient Blood Management</li> <li>- B.Braun : scientific consultancy sepsis</li> <li>- Med Update GmbH : Scientific Director</li> <li>- Biotest : Study meeting</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Nordic Group : Aprotinin registry</li> <li>- Haemonetics : Blood</li> <li>- CSL Behring : Coagulation</li> <li>- Vifor Pharma : iv iron</li> <li>- Pharmacosmos : iv iron</li> <li>- Implantcast GmbH : PBM</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Zacharowski Kai	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself - President of the European Society of Anaesthesiology &amp; Intensive Care (ESAIC)</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abd Elhamid Basem	<p><b>2021</b></p> <p>Nothing to be declared</p>
Aboyans Victor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Novo-Nordisk : Diabetes</li> <li>- Astrazeneca : Diabetes</li> <li>- Boehringer Ingelheim : Diabetes</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of the French Society of Cardiology</li> </ul>
Ahrens Ingo	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Anitihrombotic Therapy</li> <li>- Bristol Myers Squibb : Antithrombotic Therapy</li> <li>- Astra Zeneca : Antithrombotic Therapy, Heart Failure</li> <li>- Bayer Vital : Antithrombotic Therapy, Heart Failure</li> <li>- Daiichi Sankyo : Antithrombotic Therapy, Lipid lowering Therapy</li> <li>- Boehringer-Ingelheim : Heart Failure</li> <li>- Novartis : Heart Failure</li> </ul>



## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Ahrens Ingo	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Vifor International : Heart Failure, RAAS-Inhibition</li> <li>- Amgen : Lipd lowering Therapy, Atherosclerosis</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Clinical registry (AF and PCI)</li> </ul>
Aidargaliyeva Nazipa	<p><b>2021</b></p> <p>Nothing to be declared</p>
Antoniou Sotiris	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : speaker fees for education - AF</li> <li>- Bayer AG : speaker fees for education - AF</li> <li>- Daiichi Sankyo : speaker fees for education -AF</li> <li>- Astra Zeneca : speaker fees for education - CVD</li> <li>- Boehringer-Ingelheim : speaker fees for education - CVD</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Joint working initiative on improving CV care</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of Arrhythmia alliance medical advisory panel</li> </ul>
Archbold Andrew	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Asteggiano Riccardo	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself - Council of Cardio-Oncology ESC : cardio-oncology</p>
Atar Dan	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  <ul style="list-style-type: none"> <li>- Pfizer : Anticoagulation</li> <li>- Bayer Healthcare : Anticoagulation</li> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- MSD : Anticoagulation</li> <li>- Boehringer-Ingelheim : Anticoagulation and Heart Failure</li> <li>- Roche Diagnostics : Cardiac biomarkers</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Vifor International : Heart failure</li> <li>- Amgen : Lipid lowering</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Actelion : Pulmonary Artery Hypertension (DSMB)</li> <li>- Idorsia : Rheumatology (DSMB)</li> <li>- GlaxoSmithKline : Side effects of NSAIDs</li> </ul> </p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself  <ul style="list-style-type: none"> <li>- Pfizer : Anticoagulation</li> <li>- Bayer Healthcare : Anticoagulation</li> </ul> </p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Atar Dan	<b>2021</b> <ul style="list-style-type: none"> <li>- Roche Diagnostics : Cardiac biomarkers</li> <li>- Medtronic : Heart rhythm monitoring</li> </ul>
Aune Erlend	<b>2021</b>  Nothing to be declared
Badila Elisabeta	<b>2021</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Atrial Fibrillation</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Vifor Pharma : Heart Failure</li> <li>- Servier : Hypertension</li> <li>- Berlin Chemie AG : Hypertension</li> <li>- Krka Pharma : Hypertension</li> <li>- Terapia : Hypertension</li> <li>- Bayer : Venous Thrombosis, Atrial Fibrillation</li> </ul> Travel and meeting support from healthcare industry, independent of the above activities.For yourself <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Cardio Update Europe (online)</li> <li>- Servier : Heart Failure Congress (online)</li> </ul>
Banu Cristiana	<b>2021</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial Fibrillation</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Banu Cristiana	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Pfizer : Atrial Fibrillation</li> <li>- Bayer : Atrial fibrollation</li> <li>- Boehringer-Ingelheim : Diabetes</li> </ul>
Bartus Stanislaw	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- General Electric : contrast</li> <li>- Volcano : Imagiang</li> <li>- Edwards Lifesciences : interventional cardiology</li> <li>- Medtronic : interventional cardiology</li> <li>- Biotronik : interventional cardiology</li> <li>- Astra Zeneca : Pharma</li> <li>- Boehringer-Ingelheim : Pharma</li> <li>- Novartis : Pharma</li> <li>- Sanofi Aventis : PHarma</li> <li>- Bayer : pharmacotherapy</li> <li>- Abbott : Physiology, OCT imaging</li> </ul>
Batalli Arlind	<p><b>2021</b></p> <p>Nothing to be declared</p>
Baumbach Andreas	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Baumbach Andreas	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Faraday : Infarct size reduction</li> <li>- Microport : Stents</li> <li>- Sinomed : Stents</li> <li>- Medtronic : Valves</li> <li>- Pi-Cardia : Valves</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Abbot Vascular : OCT</li> </ul>
Baumgartner Helmut	<p><b>2021</b></p> <p>Nothing to be declared</p>
Beleslin Branko	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Alkaloid : antithrombitic therapy</li> </ul>
Ben Halima Afef	<p><b>2021</b></p> <p>Nothing to be declared</p>
Bertelli Luca	<p><b>2021</b></p> <p>Nothing to be declared</p>
Biteker Murat	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Boehm Michael	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Cardiology</li> <li>- Amgen : Cardiology</li> <li>- Astra Zeneca : Cardiology</li> <li>- Bayer : Cardiology</li> <li>- Boehringer-Ingelheim : Cardiology</li> <li>- Medtronic : Cardiology</li> <li>- Novartis : Cardiology</li> <li>- Servier : Cardiology</li> <li>- Vifor International : Cardiology</li> <li>- Bristol Myers Squibb : Cardiology</li> <li>- Cytokinetics : Cardiology</li> </ul>
Borger Michael A	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul>
Bouزيد Mohammed El Amine	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Bsata Walid	<p><b>2021</b></p> <p>Nothing to be declared</p>
Bueno Hector	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- MEDSCAPE-the heart.org : General (antithrombotics, vaccines)</li> <li>- Astra Zeneca : Heart Failure: Observational studies on use of healthcare resources and economic costs</li> <li>- Novartis : Sacubitril-valsartan</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Antithrombotics</li> <li>- PhaseBio : Antithrombotics</li> <li>- Astrazeneca : Heart Failure</li> <li>- Boehringer Ingelheim : Heart Failure</li> <li>- Novartis : Heart Failure - Sacubitril-valsartan</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : New antithrombotics: PACIFIC-MI Trial</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Advisor and Scientific Director, National Strategy on Cardiovascular Health. Ministry of Health and Welfare. Spain's Government Vicepresident. Spanish Society of Cardiology (Until Oct 2021)</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Campbell Patricia	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Heart failure</li> <li>- Boehringer-Ingelheim : Heart Failure</li> <li>- Novartis : Heart failure</li> <li>- Pfizer : Heart failure</li> <li>- Vifor International : Heart failure</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Clinical advisory board member for Pumping Marvellous UK HF charity</li> </ul>
Celutkiene Jelena	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul>



## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Chieffo Alaide	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Coronary</li> <li>- Abbott : coronary physiology</li> <li>- Abiomed : High Risk PCI and Cadiogenic Shock</li> <li>- Edwards Lifesciences : TAVi</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abiomed : high risk PCI</li> </ul>
Chukhrukidze Archil	<p><b>2021</b></p> <p>Nothing to be declared</p>
Cikes Maja	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- GE Healthcare : Cardiovascular ultrasound</li> <li>- Amicus Therapeutics : Fabry disease</li> <li>- Astra Zeneca : Heart failure</li> <li>- Bayer : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> <li>- Krka Pharma : Heart failure</li> <li>- Llvanova : Heart failure</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure, hyperlipidaemia</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
Cohen Ariel	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Atrial Fibrillaton</li> <li>- Astra Zeneca : Heart failure</li> <li>- Novartis : Heart Failure</li> <li>- Vifor International : Heart Failure</li> <li>- Sanofi Aventis : Lipids</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Protocol on atrial fibrillation</li> <li>- Boehringer-Ingelheim : Protocol on atrial fibrillation</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Darius Harald	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Anticoagulants, COVID-19 and thrombosis</li> <li>- Boehringer Ingelheim : Anticoagulants, heart failure</li> <li>- Bristol-Meyers Squibb : Covid-19 and the heart, anticoagulants</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Travel cost reimbursement</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- German Heart Foundation, American Heart Association</li> </ul>
Delgado Victoria	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : aortic stenosis (speaker fee in 2019 &lt;1000 euro)</li> <li>- GE Healthcare : echocardiography (&lt;2000 euro)</li> <li>- Abbott Vascular : Mitral valve disease (&lt;2000 euro)</li> <li>- Edwards Lifesciences : valvular heart disease (&lt;2000 euro)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : echocardiography</li> <li>- Edwards Lifesciences : tricuspid valve disease</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Delgado Victoria	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- Member of AHA, associate editor of Circulation and JASE</li> </ul>
Devereaux Philip J	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : MINS - Advisory Board</li> <li>- quidel : MINS - Advisory Board</li> <li>- Roche Diagnostics : ProCardio Meeting</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Philips Healthcare : Cardiac monitoring</li> <li>- Abbott : MINS</li> <li>- Siemens Healthcare : MINS</li> <li>- Roche Diagnostics : MINS</li> <li>- CloudDX : PVC-RAM (remote automated monitoring)</li> </ul>
Dubois Eric	<p><b>2021</b></p> <p>Nothing to be declared</p>
Dubrava Martin	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : cardiology</li> <li>- Boehringer-Ingelheim : cardiology</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Dubrava Martin	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Servier : cardiology</li> <li>- MSD : cardiology</li> <li>- Gedeon Richter : cardiology</li> </ul>
Duncker David	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Speaker fees</li> <li>- Astra Zeneca : Speaker fees</li> <li>- Boehringer-Ingelheim : Speaker fees</li> <li>- Boston Scientific : Speaker fees</li> <li>- Medtronic : Speaker fees</li> <li>- Pfizer : Speaker fees</li> <li>- Sorin Group : Speaker fees</li> <li>- Biotronik : Speaker fees</li> <li>- Bristol Myers Squibb : Speaker fees</li> <li>- Zoll Medical : Speaker fees</li> <li>- Bayer Vital : Speaker fees</li> </ul>
Eisen Alon	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : ANTICOAGULANTS</li> <li>- Bayer : ANTICOUAGULANTS</li> <li>- Novo-Nordisk : ANTIDAIBETICS</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Eisen Alon	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : ANTIDIABETICS</li> <li>- Astra Zeneca : ANTIPLATELES AND DISLIPIDEMIA</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : RESEARCH GRANT PCSK9 INH</li> </ul>
Erglis Andrejs	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Bayer : Cardiology</li> <li>- Boehringer-Ingelheim : Cardiology</li> <li>- Novartis : Cardiology</li> <li>- Servier : Cardiology</li> <li>- MVRx : Cardiology</li> <li>- Biosensors : Interventional Cardiology</li> <li>- Boston Scientific : Interventional Cardiology</li> <li>- Abbott Vascular : Interventional Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- HeartFlow : Interventional Cardiology</li> <li>- Research Company AS "SISTEMU INOVACIJAS" : Interventional Cardiology</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Falk Volkmar	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> <li>- Boston Scientific : Study</li> <li>- Biotronik : Study</li> <li>- Liva Nova : Study</li> </ul>
Fauchier Laurent	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Healthcare</li> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- Novo-Nordisk : Healthcare</li> <li>- Zoll Medical : Healthcare</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<b>2021</b> - XO : Healthcare
Felice Tiziana	<b>2021</b> Nothing to be declared
Ferreiro Jose Luis	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Abbott : Antithrombotic therapy - Astra Zeneca : Antithrombotic therapy - Pfizer : Antithrombotic therapy - Ferrer Internacional : Antithrombotic therapy - Bristol Myers Squibb : Antithrombotic therapy
Fras Zlatko	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Boehringer-Ingelheim : diabetes mellitus, anticoagulation - Amgen : lipid treatment - Sanofi Aventis : lipid treatment - Novartis : lipids, heart failure  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Novartis : lipidology - lipoprotein (a)
GROSU Aurel	<b>2021</b> Nothing to be declared



## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Habib Gilbert	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Genzyme : cardiomyopathy</li> <li>- General Electric : echocardiography</li> <li>- Astra Zeneca : heart failure</li> <li>- Novartis : heart failure</li> <li>- Actelion : Pulmonary hypertension</li> <li>- Abbott : valve disease</li> </ul>
Hasdai David	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : antiplatelet, diabetes</li> <li>- Boehringer-Ingelheim : diabetes</li> <li>- Sanofi Aventis : lipids</li> </ul>
Held Claes	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Advisory board</li> <li>- Astrazeneca : Advisory board</li> <li>- Coala Life : Advisory board</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Held Claes	<p><b>2021</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Research grants (institutional)</li> </ul>
Hrafnkelsdottir Thordis	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Cardiology</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of Hjartaheill, patient organisation in Iceland</li> </ul>
Huber Kurt	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antithrombotic therapy and Heart Failure therapy</li> <li>- Daiichi Sankyo : Antithrombotic therapy and Lipid Lowering Therapy</li> <li>- Astrazeneca : Antithrombotic therapy and Heart Failure Therapy and Lipid Lowering Therapy</li> <li>- Amgen : Lipid Lowering Therapy</li> <li>- Sanofi Aventis : Lipid Lowering Therapy</li> <li>- Novartis : Lipid Lowering Therapy and Heart Failure Therapy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Basic Research in Lipid Lowering Therapy (pleiomorphic effects)</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Irtiyuga Olga	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Aspen Pharma : Coagulation</li> <li>- Pfizer : Coagulation, Atrial Fibrillation</li> <li>- Roche Diagnostics : Coagulation, valvular heart disease</li> </ul>
Iung Bernard	<p><b>2021</b></p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : heart failure</li> </ul>
Jarai Zoltan	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : speaker fee</li> <li>- Boehringer-Ingelheim : speaker fee</li> <li>- Organon : speaker fee</li> <li>- Bayer : speaker fee, advisory board fee</li> <li>- Novartis : speaker fee, advisory board fee</li> <li>- Pfizer : speaker fee, advisory board fee</li> <li>- Sanofi Aventis : speaker fee, advisory board fee</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Jarai Zoltan	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Berlin Chemie AG : speaker fee, advisory board fee</li> <li>- Teva Pharmaceutical Industries : speaker fee, advisory board fee</li> <li>- Novo-Nordisk : speaker fee, advisory board fee</li> <li>- Egis Pharma : speaker fee, advisory board fee</li> <li>- Krka Pharma : speaker fee, advisory board fee</li> </ul>
Kafkas Nikolaos	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Clinical trial</li> </ul>
Karakiriou Maria	<p><b>2021</b></p> <p>Nothing to be declared</p>
Knuuti Juhani	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Imaging study protocol review</li> <li>- GE Healthcare : Imaging study protocol review, speaker fee</li> <li>- Bayer : Speaker fee</li> <li>- Boehringer-Ingelheim : Speaker fee</li> <li>- Pfizer : Speaker fee</li> <li>- Merck Sharp &amp; Dohme : Speaker fee</li> <li>- Lundbeck : Speaker fee</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Konradi Aleksandra	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> <li>- Servier : hypertsniion</li> </ul>
Koskinas Konstantinos	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul>
Kotecha Dipak	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> <li>- MyoKardia : Trial Advisory Board</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> <li>- Protherics Medicines Development : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul>
Kristensen Steen Dalby	<p><b>2021</b></p> <p>Nothing to be declared</p>
Landmesser Ulf	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> <li>- Sanofi Aventis : Speaker fee</li> <li>- Bayer AG : Speaker fee</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2021</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Amgen : Research grant</li> <li>- Bayer AG : Research Grant</li> </ul>
Lewis Basil S	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Idorsia : Antithrombotics</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
Linhart Ales	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Avrobio : Faby disease</li> <li>- Novartis : Heart failure</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lochen Maja-Lisa	<p><b>2021</b></p> <p>Nothing to be declared</p>
Lunegova Olga	<p><b>2021</b></p> <p>Nothing to be declared</p>
Macas Andrius	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Sana net, Lithuania : bleeding management</li> <li>- Berlin Chemie AG : Pain management, bleeding management, anticagulation</li> </ul>
Maeng Michael	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novo Nordisk : Diabetes and cardiology</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Risk stratification of patient with chronic coronary artery disease</li> </ul>
Manzo-Silberman Stephane	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS</li> <li>- Boehringer-Ingelheim : AF PCI</li> <li>- Bayer Healthcare : AF PCI</li> <li>- Exeltis : contraceptive drug</li> </ul>



## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Manzo-Silberman Stephane	<b>2021</b> <ul style="list-style-type: none"> <li>- Novo-Nordisk : diabetes</li> <li>- Organon : dyslipidemia</li> <li>- Biotronik : PCI</li> </ul>
Metzler Bernhard	<b>2021</b>  Nothing to be declared
Meyer Philippe	<b>2021</b>  Financial Declaration  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Abbott : Heart Failure</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Bayer : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Pfizer : Heart Failure</li> <li>- Servier : Heart Failure</li> <li>- Vifor International : Heart Failure</li> </ul> Travel and meeting support from healthcare industry, independent of the above activities.For yourself <ul style="list-style-type: none"> <li>- Vifor International : Heart failure congresses</li> </ul> Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself <ul style="list-style-type: none"> <li>- Novartis : Heart Failure</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Milanova Maria	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : ACS</li> <li>- CRI GmbH : ACS</li> <li>- Boehringer-Ingelheim : ACS, anticoagulation, HF</li> <li>- Merck Sharp &amp; Dohme : beta blockers</li> <li>- Amgen : familial dyslipidemia</li> <li>- Astra Zeneca : HF</li> <li>- Novartis : HF</li> <li>- Servier : hypertension</li> </ul>
Mindham Richard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Neubeck Lis	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pfizer : Atrial fibrillation</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Medical advisor to the Atrial Fibrillation Alliance</p>
Nielsen Jens Cosedis	<p><b>2021</b></p> <p>Nothing to be declared</p>
Oh Ilka	<p><b>2021</b></p> <p>Nothing to be declared</p>
Pasquet Agnes A	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Daiichi Sankyo : general cardiology - Servier : general cardiology - Philips : imaging</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - member of the Belgian Society of Cardiology</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Pejkov Hristo	<p><b>2021</b></p> <p>Nothing to be declared</p>
Petersen Steffen Erhard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
Prescott Eva	<p><b>2021</b></p> <p>Nothing to be declared</p>
Rakisheva Amina	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Bayer : Atrial Fibrillation - Novartis : Heart Failure</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Ruusalepp Arno	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : valve and annuloplasty ring postmarket study</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : educational grant</li> </ul>
Saade Georges	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Speaker fees</li> <li>- Bayer : Speaker fees</li> <li>- Boehringer-Ingelheim : Speaker fees</li> <li>- Novartis : Speaker fees</li> <li>- Pfizer : Speaker fees</li> <li>- Servier : Speaker fees</li> </ul>
Santos Mario	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Heart Failure</li> <li>- Novartis : Heart failure</li> <li>- Janssen-Cilag : Pulmonary hypertension</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Santos Mario	<p><b>2021</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Heart Failure</li> <li>- Novartis : Heart Failure</li> </ul>
Saraste Antti	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Heart failure /Advisory board fee</li> <li>- Astra Zeneca : Heart failure and coronary artery disease /speaker and advisory board fees</li> <li>- Abbott : Structural heart disease /speaker fee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Precordior : Heart failure</li> <li>- Astra Zeneca : Heart failure, Coronary artery disease</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Scientific advisory committee member of Finnish Foundation for Cardiovascular Research</li> </ul>
Shumavets Vadim	<p><b>2021</b></p> <p>Nothing to be declared</p>
Sibbing Dirk	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Anticoagulants</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sibbing Dirk	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Bayer AG : Anticoagulants</li> <li>- Daiichi Sankyo : Antiplatelets</li> <li>- Sanofi Aventis : Antiplatelets</li> </ul>
Siller-Matula Jolanta	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulants</li> <li>- Chiesi Pharma : Antiplatelet therapy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- AOP Orphan Pharmaceuticals : Arrhythmia</li> </ul>
Sisakian Hamayak	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : lecture honorarium</li> </ul>
Sitges Marta	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Rovi : Heart Failure</li> <li>- Amgen : Hypercholesterolemia</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>
Skalicka Hana	<p><b>2021</b></p> <p>Nothing to be declared</p>
Skoric Bosko	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- JGL : antihypertensives</li> <li>- Biotest : Cytotect in heart transplantation</li> <li>- Astra Zeneca : dapagliflozin</li> <li>- Novartis : Entresto</li> <li>- Teva Pharmaceutical Industries : heart failure</li> <li>- Bayer : NOAC</li> <li>- Krka Pharma : prasugrel</li> <li>- Berlin Chemie AG : ranolazine</li> <li>- Sandoz : ticagrelor</li> </ul>



## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Smajic Elnur	<p><b>2021</b></p> <p>Nothing to be declared</p>
Sokolov Maksym	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : speaker fees for conferences in the field of cardiology: antiplatelet and anticoagulant therapy for patients with AMI and chronic coronary syndromes</li> </ul>
Soufiani Aida	<p><b>2021</b></p> <p>Nothing to be declared</p>
Stankovic Ivan	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension</li> <li>- Boehringer-Ingelheim : Atrial fibrillation</li> <li>- Pfizer : Atrial fibrillation</li> <li>- Astra Zeneca : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Merck Sharp &amp; Dohme : Pulmonary hypertension</li> </ul>
Storey Robert	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antiplatelet therapy</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Storey Robert	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Idorsia : Antiplatelet therapy</li> <li>- Astrazeneca : Antiplatelet therapy, Glucose-lowering therapy</li> <li>- Bristol Myers Squibb/Pfizer : Antithrombotic therapy</li> <li>- Hengrui : Antithrombotic therapy</li> <li>- PhaseBio : Cardiovascular therapeutics</li> <li>- Novartis : Lipid-lowering therapy</li> <li>- Alnylam : Lipid-lowering therapy</li> <li>- CSL Behring : Lipid-lowering therapy</li> <li>- Cytosorbents : Surgical device, antithrombotic therapy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Glycardial Diagnostics : Cardiovascular biomarker</li> <li>- Cytosorbents : Surgical device, antithrombotic therapy</li> </ul>
ten Berg Jurrien M	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS</li> <li>- Boehringer-Ingelheim : ACS</li> <li>- Ferrer Internacional : ACS</li> <li>- Bayer : AF</li> <li>- Pfizer : AF</li> </ul>
Thielmann Matthias	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Touyz Rhian	<p><b>2021</b></p> <p>Nothing to be declared</p>
Urbinati Stefano	<p><b>2021</b></p> <p>Nothing to be declared</p>
Valtola Kati	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : cardiology</li> <li>- Sanofi Aventis : cardiology</li> <li>- Amgen : coronary disease</li> <li>- Boehringer-Ingelheim : coronary disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Genzyme : Fabry disease</li> </ul>
Vukmirovic Mihailo	<p><b>2021</b></p> <p>Nothing to be declared</p>
Zakirov Nodir U	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- OlainFarm : antiarrhythmic drug, Aethacizinum</li> <li>- Bayer AG : anticoagulation, Xarelto</li> <li>- Promed Cs : propafenone</li> <li>- Acino : bisoprolol</li> </ul>

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry	
Zakirov Nodir U	2021	- Nobel pharma : rosuvastatin

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Aboyans Victor	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Bristol Myers Squibb : Antithrombotic therapies</li> <li>- Astrazeneca : Diabetes</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Peripheral Artery Disease</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Aboyans Victor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Novo-Nordisk : Diabetes</li> <li>- Astrazeneca : Diabetes</li> <li>- Boehringer Ingelheim : Diabetes</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of the French Society of Cardiology</li> </ul>
Antoniou Sotiris	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : speaker fees for education - AF</li> <li>- Bayer AG : speaker fees for education - AF</li> <li>- Daiichi Sankyo : speaker fees for education -AF</li> <li>- Astra Zeneca : speaker fees for education - CVD</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Joint working initiative on improving CV care</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Antoniou Sotiris	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pfizer : speaker fees for education - AF - Bayer AG : speaker fees for education - AF - Daiichi Sankyo : speaker fees for education -AF - Astra Zeneca : speaker fees for education - CVD - Boehringer-Ingelheim : speaker fees for education - CVD</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Astra Zeneca : Joint working initiative on improving CV care</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p>
Arbelo Elena	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biosense Webster : Atrial fibrillation</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Arbelo Elena	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial fibrillation</li> </ul>
Asteggiano Riccardo	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> <li>- Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Council of Cardio-Oncology ESC : cardio-oncology</li> </ul>
Baigent Colin	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Cardiovascular and renal disease</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Renal disease</li> </ul>
Baumbach Andreas	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Pharmacology</li> <li>- CERC : Research Organisation: Events Committees</li> <li>- Abbot Vascular : Stents</li> <li>- Microport : Stents</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Baumbach Andreas	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Sinomed : Stents</li> <li>- Venus Medtech : Valves, CEP</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet</li> <li>- Faraday : Infarct size reduction</li> <li>- Microport : Stents</li> <li>- Sinomed : Stents</li> <li>- Medtronic : Valves</li> <li>- Pi-Cardia : Valves</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Abbot Vascular : OCT</li> </ul>
Borger Michael A	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Borger Michael A	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Medtronic : heart valve therapy</li> </ul>
Celutkiene Jelena	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Amgen : heart failure</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : heart failure</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation, amyloidosis</li> <li>- Astra Zeneca : coronary heart disease</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Orion : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure</li> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- GE Healthcare : Cardiovascular ultrasound</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Amicus Therapeutics : Fabry disease</li> <li>- Astra Zeneca : Heart failure</li> <li>- Bayer : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> <li>- Krka Pharma : Heart failure</li> <li>- Llvanova : Heart failure</li> <li>- Novartis : Heart failure, hyperlipidaemia</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
Collet Jean-Philippe	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Lipids</li> <li>- Astra Zeneca : Post-PCI antiplatelet treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p><b>2020</b> - Bristol Myers Squibb : Post-TAVR antithrombotic treatment</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : post PCI antithrombotic therapy</li> <li>- Pfizer : POST PCI ANTITHROMBOTIC THERAPY</li> <li>- Terumo Inc : POST PCI ANTITHROMBOTIC THERAPY</li> <li>- Bristol Myers Squibb : Post-TAVI antithrombotic treatments</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : post tavi antithrombotic therapy</li> <li>- Bristol Myers Squibb : post-tavi antithrombotic therapy</li> </ul>
Falk Volkmar	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Falk Volkmar	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> <li>- Boston Scientific : Study</li> <li>- Biotronik : Study</li> <li>- Liva Nova : Study</li> </ul>
Fauchier Laurent	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- XO : Healthcare</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Healthcare</li> <li>- Bayer : Healthcare</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- Novo-Nordisk : Healthcare</li> <li>- Zoll Medical : Healthcare</li> <li>- XO : Healthcare</li> </ul>
Gale Christopher Peter	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acs hf</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : af</li> <li>- Abbott : diabetes</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : ACS</li> <li>- Chiesi Pharma : ACS</li> <li>- Astra Zeneca : ACS Hf</li> <li>- Boehringer-Ingelheim : AF</li> <li>- Daiichi Sankyo : AF</li> <li>- Menarini : CAD</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Bayer : CVD</li> <li>- Zydus : CVD</li> <li>- Oxford University Press : EHJQCCO</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : AF</li> <li>- Abbott : Diabetes</li> <li>- European Society of Cardiology : EuroHeart</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.For yourself</p> <ul style="list-style-type: none"> <li>- Wondrmedical</li> </ul>
Halvorsen Sigrun	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Sanofi Aventis : Lipidlowering</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart failure</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation -speaker fee</li> <li>- Bristol Myers Squibb : Anticoagulation- speaker fee</li> <li>- Novartis : heart failure - speaker fee</li> </ul>
Iung Bernard	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : heart failure</li> </ul>
Konradi Aleksandra	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Konradi Aleksandra	<p><b>2020</b> - Servier : hypertsniion</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> <li>- Servier : hypertsniion</li> </ul>
Koskinas Konstantinos	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> <li>- MyoKardia : Trial Advisory Board</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> <li>- Protherics Medicines Development : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul>
Landmesser Ulf	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory Board fee</li> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Bayer AG : Research Grant</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> <li>- Sanofi Aventis : Speaker fee</li> <li>- Bayer AG : Speaker fee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Amgen : Research grant</li> <li>- Bayer AG : Research Grant</li> </ul>
Lewis Basil S	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Vifor International : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lewis Basil S	<p><b>2020</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Idorsia : Antithrombotics</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
Linhart Ales	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Linhart Ales	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Avrobio : Faby disease</li> <li>- Novartis : Heart failure</li> </ul>
Lochen Maja-Lisa	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Mindham Richard	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Imperial College, London : 3 honoraria totalling GB£500/€550, passed in full to UK charity, CardiomyopathyUK. There will be no more honoraria.</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- I support actively the British charity CardiomyopathyUK and make a monthly payment to support their activites. I also passed the three honoraria in 2A to CardiomyopathyUK, in full.</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Re item 7A: I have shares which are held inside and outside of a pension. I am unaware of what the shares are as they are all managed by a portfolio manager. Consequently I do not know whether I hold any shares in healthcare or healthcare-related companies, or in media or education companies.</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
Nielsen Jens Cosedis	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Danish Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I received institutional research grants from the Novo Nordisk Foundation</p> <hr/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Petersen Steffen Erhard	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself            - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. For yourself            - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself            - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. For yourself            - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. For yourself            - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
Prescott Eva	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Rakisheva Amina	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillatuion</li> <li>- Novartis : Heart Failure</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillatuion</li> <li>- Novartis : Heart Failure</li> </ul>
Sitges Marta	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Rovi : Heart Failure</li> <li>- Amgen : Hypercholesterolemia</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>
Touyz Rhian	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Consultancy-expert opinion</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Nothing to be declared</p>